Velasof Velpatasvir Sofosbuvir Tablets

                                      Velasof Tablets  

Velasof is an anti-hepatitis C viral medicine, containing active components known as Sofosbuvir and Velpatasvir available in the strength of 400mg & 100mg respectively. Velpatasvir is a class of anti-hepatitis C viral drug, called NS5A multiplication complex inhibitors. This may have combined with other anti-viral agent Sofosbuvir which expels its work by stopping the virus which may causes hepatitis C viral infection from spreading inside the body. Velasof tablet is not a curable; it is only used to control the spreading of disease.  

Velasof tablet

                         VELASOF INDICATION AND USAGE

• Velasof tablets are used only in adult’s patients with long lasting hepatitis C virus caused by genotypes I, II, III, IV, V or VI In two conditions Velasof tablets are used; 

• Without cirrhosis or with compensated cirrhosis (child Pugh A or B) With decompensated cirrhosis by combining with ribavirin (child Pugh C) 

                         VELASOF MECHANISM OF ACTION

• Both the components in Velasof tablets are involved in inhibiting nonstructural protein which is essential for viral multiplication. Sofosbuvir is a NS5B inhibitor, whereas Velpatasvir is considered as NS5Ainhibitor Velasof is a directly acting anti-hepatitis C viral agent. 

• Sofosbuvir leads to produce pharmacologically active uridine analog triphosphate by intracellular metabolism. Sofosbuvir is inserted into viral HCV DNA by NS5B polymerase and act as a chain terminator. Velpatasvir inhibits NS5A protein which is responsible for viral assembly.

                         VELASOF UNDERGOES ADME PROPERTY

• The peak plasma concentration time of Sofosbuvir and Velpatasvir is 0.5 to 1 hour and 3 hours respectively. The effect of food with Velasof tablet determines as; With moderate meal: Sofosbuvir increases to 60%; increases to 34% With high fat meal: Sofosbuvir increases to 78%; increases to 21% The blood plasma ratio of Sofosbuvir & Velpatasvir is 0.7 & 0.52 to 0.67 respectively 

• The human plasma protein bound; Sofosbuvir & Velpatasvir is 61 to 65% &>99.5% respectively. The metabolism of Sovihep occurs; Sofosbuvir: cathepsin A, or carboxyl esterase Velpatasvir: CYP2B6, CYP2C8 or CYP3A4 

• The elimination of Velasof occurs via; Sofosbuvir: Glomerular filtration, active tubular secretion Velpatasvir: biliary excretion The terminal half-life of Velasof tablets; Sofosbuvir: 0.5 hours; GS331007: 25 hours & Velpatasvir 15 hours Elimination of Sofosbuvir in urine at 80%; feces at 14% Elimination of Velpatasvir in urine 0.4%; feces at 94%    

                         VELASOF CAUSES UNDESIRABLE EFFECTS

• Headache, Fatigue, Nausea, Asthenia, Insomnia, Anemia, HBV reactivation, Elevation of lipase & amylase levels, Elevation of creatine kinase, Cardiac disorder like bradycardia while concomitant with amiodarone, Angioedema, Skin rashes   

                          VELASOF PRECAUTIONS

• Exposure of hepatitis B viral infection occurs in HBV/HCV co infections Serious symptomatic bradycardia while concomitant with amiodarone Risk of depletion of therapeutic effect occurs due to combination of Velasof with P-gp inducers or CYP3A4 inducers. 

• Fetal adverse occurs while concomitant with ribavirin For all these conditions, withhold or discontinue the therapy with Velasof tablets.